<i>Materials and Methods</i>: In this multicenter retrospective study, we evaluated patients with stage II-III HER2-positive breast cancer who received pertuzumab-based neoadjuvant therapy followed by surgery between January 2023 and June 2025 across six oncology centers in Türkiye. Here, ERBB2 is linked to breast cancer.